• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Climb Bio Inc.

    6/5/25 4:05:36 PM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLYM alert in real time by email
    8-K
    false 0001768446 0001768446 2025-06-04 2025-06-04
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 4, 2025

     

     

    CLIMB BIO, INC.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-40708   83-2273741

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    20 William Street, Suite 145

    Wellesley Hills, Massachusetts

      02481
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (866) 857-2596

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.0001 per share   CLYM  

    The Nasdaq Stock Market LLC

    (The Nasdaq Global Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    Climb Bio, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders on June 4, 2025. The following is a summary of the matters voted on at that meeting.

     

      1.

    The stockholders of the Company elected Judith Dunn, Ph.D., and Stephen Thomas, Ph.D., to the Company’s board of directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor has been duly elected and qualified. The results of the stockholders’ vote with respect to such matter were as follows:

     

         Votes For      Votes
    Withheld
         Broker Non-
    Votes
     

    Judith Dunn, Ph.D.

         36,827,909        6,615,228        10,126,633  

    Stephen Thomas, Ph.D.

         41,359,959        2,083,178        10,126,633  

     

      2.

    The stockholders of the Company ratified the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the stockholders’ vote with respect to such matter were as follows:

     

    Votes For

     

    Votes Against

     

    Abstentions

    53,442,396   8,780   118,594


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

          Climb Bio, Inc.
    Date: June 5, 2025     By:  

    /s/ Aoife Brennan

                Aoife Brennan, M.B., Ch.B.
                President and Chief Executive Officer
    Get the next $CLYM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLYM

    DatePrice TargetRatingAnalyst
    6/6/2025$10.00Outperform
    Oppenheimer
    5/22/2025$7.00Buy
    BTIG Research
    12/2/2024$10.00Outperform
    Leerink Partners
    More analyst ratings

    $CLYM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Climb Bio with a new price target

      Oppenheimer initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

      6/6/25 8:35:04 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Climb Bio with a new price target

      BTIG Research initiated coverage of Climb Bio with a rating of Buy and set a new price target of $7.00

      5/22/25 8:24:05 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Climb Bio with a new price target

      Leerink Partners initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $10.00

      12/2/24 9:55:08 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

      Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

      6/18/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company's 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted to one new employee on May 19, 2025, and consisted of a non-statutory stock option to purchase up to an aggregate of 120,000 shares of common stock of the Company. The option has an ex

      5/19/25 4:34:52 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

      Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarte

      5/14/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Brennan Aoife converted options into 68,750 shares and sold $25,154 worth of shares (20,618 units at $1.22) (SEC Form 4)

      4 - Climb Bio, Inc. (0001768446) (Issuer)

      7/1/25 4:37:17 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Thomas Stephen Basil converted options into 25,094 shares, increasing direct ownership by 14% to 204,282 units (SEC Form 4)

      4 - Climb Bio, Inc. (0001768446) (Issuer)

      7/1/25 4:32:24 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Wilson Perrin Megan

      3 - Climb Bio, Inc. (0001768446) (Issuer)

      6/23/25 4:15:07 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Climb Bio Inc.

      SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)

      11/14/24 9:29:34 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    SEC Filings

    See more
    • SEC Form 8-K filed by Climb Bio Inc.

      8-K - Climb Bio, Inc. (0001768446) (Filer)

      6/18/25 7:08:36 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Climb Bio Inc.

      8-K - Climb Bio, Inc. (0001768446) (Filer)

      6/5/25 4:05:36 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Climb Bio Inc.

      DEFA14A - Climb Bio, Inc. (0001768446) (Filer)

      5/23/25 4:32:18 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLYM
    Leadership Updates

    Live Leadership Updates

    See more
    • Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

      Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

      6/18/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

      WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight

      4/1/25 7:00:00 AM ET
      $ABOS
      $CLYM
      $LENZ
      $SLDB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer

      WELLESLEY HILLS, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry. "I am delighted to welcome Dr. Perrin Wilson to the Climb Bio management team," said Aoife Brennan, President and CEO of Climb Bio. "Perrin brings extensive experience and a track record of success across large pharma and biotech to Climb Bio. As Chief Business Officer, she will lead the Company's pre-commercial planning, communications, and business development efforts. Perrin's proven expertise in negotiat

      2/24/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care